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Artemisinin-based combination therapies are recommended by the World Health Organisa-
tion (WHO) as first-line treatment for Plasmodium falciparummalaria, yet medication must
be of good quality for efficacious treatment. A recent meta-analysis reported 35% (796/
2,296) of antimalarial drug samples from 21 Sub-Saharan African countries, purchased
from outlets predominantly using convenience sampling, failed chemical content analysis.
We used three sampling strategies to purchase artemisinin-containing antimalarials (ACAs)
in Enugu metropolis, Nigeria, and compared the resulting quality estimates.
Methods
ACAs were purchased using three sampling approaches - convenience, mystery clients
and overt, within a defined area and sampling frame in Enugu metropolis. The active phar-
maceutical ingredients were assessed using high-performance liquid chromatography and
confirmed by mass spectrometry at three independent laboratories. Results were express-
ed as percentage of APIs stated on the packaging and used to categorise each sample as
acceptable quality, substandard, degraded, or falsified.
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Results
Content analysis of 3024 samples purchased from 421 outlets using convenience (n=200),
mystery (n=1,919) and overt (n=905) approaches, showed overall 90.8% ACAs to be of ac-
ceptable quality, 6.8% substandard, 1.3% degraded and 1.2% falsified. Convenience sam-
pling yielded a significantly higher prevalence of poor quality ACAs, but was not evident by
the mystery and overt sampling strategies both of which yielded results that were compara-
ble between each other. Artesunate (n=135; 4 falsified) and dihydroartemisinin (n=14)
monotherapy tablets, not recommended by WHO, were also identified.
Conclusion
Randomised sampling identified fewer falsified ACAs than previously reported by conve-
nience approaches. Our findings emphasise the need for specific consideration to be given
to sampling frame and sampling approach if representative information on drug quality is to
be obtained.
Introduction
Plasmodium falciparum (Pf) causes 207 million malaria cases each year, resulting in 562,000
deaths [1]. Artemisinin-based combination therapies (ACTs) are recommended by the World
Health Organisation (WHO) as first-line treatment for Pfmalaria. Efficacious malaria control
and treatment requires the use of good quality medication [1] Substandard, degraded and falsi-
fied (also referred to as counterfeit or spurious medicines) ACTs pose a threat to malaria pa-
tients [2] and may accelerate the spread of drug resistance [3].
Ad hoc surveys in South East Asia have found up to half of artesunate monotherapy tablets
were falsified [4–9]. Falsified monotherapies and ACTs have also been reported in Africa,
where there is a high burden of potentially fatal Pfmalaria [10]. With 48 million clinical epi-
sodes and 180,000 deaths per year, Nigeria is the single most heavily malaria-burdened country
in the world. Malaria accounts for 60% of outpatient visits, 30% of hospitalizations under five
years of age [11], and 11% of maternal deaths [12]. In 2005 Nigeria adopted the ACT arte-
mether/lumefantrine as the first-line treatment for uncomplicated malaria at public health fa-
cilities, and subsequently added artesunate/amodiaquine [13]. In Southeast Nigeria in 2008,
27% of non-ACT antimalarial drugs (60 out of 225) did not meet the United States Pharmaco-
poeia (USP) quality specifications for dissolution testing [14]; ACT formulations were not
obtainable in that region at the time.
The considerable technical, financial and human resources required to inspect, analyse and
police the drug supply are lacking in most malaria endemic countries. A systematic review of
literature reported that studies that used strong methodology were few and majority did not
differentiate between substandard and counterfeit medicines [15]. Sample collection methods
require epidemiological knowledge and an adequate sample size to provide a suitable estimate
of prevalence which would subsequently justify and promote the political will to put in place
mechanisms needed to assure drug quality [16].
This study reports the findings of different sampling approaches (convenience, mystery cli-
ents and overt) on the prevalence and, estimates of poor quality artemisinin-containing anti-
malarials (ACAs) in a single geographical area.
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Methods
Study area and sample collection
Enugu metropolis (S1 Fig), Southeast Nigeria, with a population of 3.3 million, bears 1.1% of
the national malaria burden of 3,300 annual malaria deaths.[13]. Pf is the most prevalent para-
site and the state is considered holo-endemic for malaria [17].
Convenience approach. This frequently-used purposeful sampling involves the surveyors
purchasing medicines without specific guidance on which outlets to sample [18]. A geo-
referenced list of all government facilities and outlets selling ACAs was obtained from a related
project (Research on the Economics of Artemisinin Combination Therapies—REACT) [19].
These 372 outlets were concentrated in three main local government areas: Enugu East, Enugu
North and Enugu South. The REACT list was verified in June 2012 to check that they were still
operating prior to purchasing the ACAs. A total of 23 outlets (pharmacies and patent medicine
vendors) were selected for sampling based on geographical ratio: Enugu East 94 outlets (25%);
Enugu North 149 outlets (40%); Enugu South 129 outlets (35%), i.e. 5:8:7. A total of 200 sam-
ples were purchased by selecting one sample of every available brand of artemisinin combina-
tion therapy (ACT) and artemisinin monotherapy (AMT) from each of the 23 outlets, by four
surveyors over seven days.
Mystery client approach. Sampling was based on the previous census above and a list ob-
tained from the Ministry of Health (director of pharmacy). Eight teams of two 'mystery client'
surveyors updated the two lists in December 2012 to verify which outlets were still trading and
to add new outlets. The updated list comprised a total of 489 outlets (138 pharmacies, 307 pat-
ent medicine vendors and 44 public health facilities), of which 279 were found to sell ACAs
(not all outlets listed sold them). In order to sample for ACTs one surveyor approached the
provider masquerading as a patient or their care-giver, or stating that they needed to send the
most effective antimalarials to relatives in a village and asked to see all ACAs before purchasing
as many as possible without raising suspicion. The other surveyor remained outside the outlet
and covertly recorded its Global Positioning System (GPS) co-ordinates.
Overt approach. The sampling frame was updated in February 2013, as part of an overt
survey undertaken by four teams of two surveyors. A total of 119 outlets were visited using this
overt sampling approach, of which 98 had previously been visited during the mystery client
survey. The provider was informed of the purpose of the drug purchase and their consent
sought to participate in the study. An outlet questionnaire was completed before purchases to
document the availability, supply and cost of ACAs, as well as provider's level of training.
Sample processing and laboratory analyses
For every sample purchased, the outlet type, date of purchase, price paid, brand name, formula-
tion, batch number, manufacture and expiry date were recorded on a standard form. Every
sample was placed in an individual zip-lock bag together with data recorded on their respective
questionnaires and stored securely in an air conditioned room (20°C) pending dispatch
using, DHL Express, to the London School of Hygiene and Tropical Medicine (LSHTM), Lon-
don, UK for further processing.
Digital photographs of packaging and contents were taken and sample information (brand
name, stated active pharmaceutical ingredients (APIs), dose form, outlet, district, date of pur-
chase, name of stated manufacturer, country of manufacture, National Agency for Food and
Drug Administration and Control (NAFDAC) registration number, presence of the Affordable
Medicines Facility—malaria (AMFm) logo (green leaf), batch number, date of manufacture,
expiry date, number of tablets per packet and price paid) checked with the information
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collected in the field and logged in a data collection tool (Epi Info v.3.5.) [20]. Tablets were
weighed and their dimensions recorded prior to laboratory analysis.
Chemical content analysis
For quantitative analysis by high performance liquid chromatography (HPLC), tablets were
dissolved in a solvent (S1 Table), sonicated and centrifuged. The supernatant was then injected
into the HPLC column and the amount of APIs present in the tablet was determined. Injectable
forms of antimalarials and suppositories were dissolved in methanol prior to HPLC analysis.
HPLC analysis was conducted using a Dionex Ultimate 3000 system (Thermofisher, Hemel
Hempstead, UK) and separation achieved using a GENESIS AQ 4 μm column (150 x 4.6 mm,
Grace Materials Technologies, Cranforth, UK) or Acclaim 120, C18, 5 μm Analytical (4.6 x 150
mm) from Fisher Scientific, Leicestershire, UK. The mobile phase was a gradient of ammonium
formate (10 mM, pH 2.7) and acetonitrile (v/v; 15:85 to 85:15 over 7.0 min). A photo-diode
array detector (UV-PDA; DAD 3000) set at 204 nm for the artemisinin and the derivatives
artesunate, artemether and dihydroartemisinin, 360 nm for piperaquine, amodiaquine and
lumafantrine; 275 nm for sulfadoxine, sulfamethoxypyrazine and pyramethamine; 259 nm for
mefloquine. In all cases, the flow rate used was 1.0 mL/min. A duplicate sample of the ones
analysed at LSHTM from each packet were sent to the US Centres for Disease Control and Pre-
vention (CDC) Laboratories Atlanta, USA for confirmatory HPLC analyses, and to the Georgia
Institute of Technology (GT), Atlanta, USA for ambient mass spectrometry (MS) analyses to
verify the ingredients present and identify any unstated compounds [21, 22]. In general there
was good agreement between the results from the two laboratories where quantitation work
was carried out (CDC and LSHTM) as shown by the Bland Altman plots (S2 Fig).
Classification of samples
Laboratory results were expressed as a percentage of the API (% API) stated on the packaging
for both APIs, the artemisinin derivative (AD) and the partner drug (PD) which is a non-arte-
misinin antimalarial. To accommodate the variation in HPLC laboratory testing of less than 10
samples of each ACA formulation, we adopted the tolerance band of 85% to 115% for the pur-
poses of this study. If the % API of a drug was found to be outside of this tolerance band then a
second sample from the same packet was reanalysed (with the exception of suspensions as the
entire bottle was used in the first analysis) and the majority outcome reported. The % API used
to classify each sample as one of the following: being of acceptable quality (85–115% for both
APIs); substandard (>0% but<85%, or>115% of either API); degraded (products of degrada-
tion of either or both APIs present); or falsified (0% APIs). Classification of analysed drugs as
“degraded” was achieved through comparison of HPLC retention times and MS patterns of
good quality drugs with that obtained from artificially degraded samples. Artificial degradation
was achieved by placing good quality artemether/lumefantrine (Coartem, Novartis, China) and
artesunate/amodiaquine tablets (Winthrop, Maphar Laboratories, Morocco) in an oven at
60°C for 21 days [23].
Data analysis
Laboratory data were combined with survey and sample data (S1 Database) and analysed using
STATA v12 (Statacorp, College station, Texas). Proportions were evaluated using Chi-square
tests and crude associations between poor quality ACAs and variables collected from the ques-
tionnaire were examined. A univariate logistic model assessed associations with poor quality
products and factors associated with a p-value<0.1 on crude analysis were included in a multi-
variate model. The svy command was used to account for clustering at the outlet level.
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by the person in charge of the outlet during the overt sampling approach which is recorded on
the database. Findings were reported to the Ministry of Health, Enugu state; manufacturers
whose products were found to have been falsified; Global Fund drug quality section and the
World Health Organisation (rapidalert@who.int).
Results
A total of 3,024 ACA samples were analysed of the 3065 purchased using the three sampling
approaches from 421 outlets (35.6% pharmacies, 60.6% patent medicine vendors, 3.6% public
health facilities, and 0.2% market stalls). Overall, approximately half of the pharmacies and
patent medicine vendors had an ACA available at the time of the overt survey, and typically
had 2–3 staff of which at least one had a local secondary school qualification (Table 1). Phar-
macies were more likely than patent medicine vendors to have staff with a health-related quali-
fication and recent malaria training (past 12 months), and on average stocked almost twice as
many ACA samples of varying brands than patent medicine vendors.
Table 2 shows the quality of ACAs found using the alternative sampling strategies. Conve-
nience sampling approach yielded 190 ACTs and 10 AMTs, representing 49 different brands,
purchased from 23 outlets. In the convenience sample 3.0% of the ACAs purchased were found
to be falsified falsified, 2.0% degraded, and 10.5% substandard (4.0% with respect to API 1;
6.0% for API 2; 0.5% for both APIs), while 84.5% were of acceptable quality. The mystery cli-
ents approach yielded 102 brands purchased from 277 outlets (1,794 ACT and 125 AMT sam-
ples); of which 1.2% were falsified, 1.3% degraded, 6.4% substandard (2.9% API 1; 1.7% API 2;
1.8% both APIs), and 91.1% were of acceptable quality drugs. The overt sampling approach re-
sulted in 846 ACTs and 59 AMTs, including 79 brands from 119 outlets. From these samples,
0.6% were falsified, 1.0% degraded, 7.0% substandard (3.8% API 1; 2.3% API 2; 0.9% both
APIs), and 91.5% were of acceptable quality. Mass Spectrometry analyses of falsified samples
confirmed the absence of the stated APIs and tentatively identified the presence of other poten-
tially harmful compounds; including bis (2-ethylhexyl) adipate, dioctyl adipate, chlorzoxazone,
ciprofloxacin and acetaminophen (S2 Table).
All the sampling approaches used detected falsified drugs; one of the falsified products was
detected amongst samples collected by at least two of the different sampling approaches. A
Table 1. Description of outlets sampled using the overt sampling approach.



























Pharmacies 83 54 (65.1%) 53 (98.1%) 3 (2,6) 51 (94.4%) 31 (57.4%) 33 (61.1%) 10.2
PMVs 163 65 (39.9%) 63 (96.9%) 2 (1,2) 60 (92.3%) 25 (38.5%) 33 (50.8%) 5.7
χ2 p-value - 0.28 0.73 - 0.54 0.14 0.40 -
Total 246 119 (48.4%) 116 (97.5%) 2 (1,3) 111 (93.3%) 56 (47.1%) 66 (55.5%) -
ACA = artemisinin-containing antimalarial; IQR = interquartile range; PMVs = patent medicine vendors.
doi:10.1371/journal.pone.0125577.t001
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significantly higher proportion of falsified drugs were found in samples purchased using the
convenience approach compared to mystery and overt approaches (Table 2, p = 0.002 and
0.046, respectively). The proportion of substandard and degraded drugs, however, did not vary
significantly between the three sampling approaches (p>0.05 in all cases).A subsample of 98
outlets were visited during both mystery and overt sampling (Table 3). From these outlets a
similar number of samples (720), brands (75; p = 0.35), and poor quality drugs (p>0.05 in
all cases) were purchased using each approach. As mystery and overt sampling approaches
showed no difference in the proportion of poor quality drugs purchased, unlike the conve-
nience approach, all subsequent STATA analyses were restricted to the overt and mystery cli-
ents data sets.
During the mystery and overt sampling over 80% of the ACAs collected were sold as tablets
and approximately a quarter of medicines were manufactured by WHO prequalified compa-
nies (Table 4). Both ACTs (2,679) and AMTs (186), including monotherapy suspensions (36),
Table 2. Quality of Artemisinin-Containing Antimalarials (ACAs) purchased per outlet using convenience, mystery clients and overt sampling ap-
proaches in Enugu, Nigeria; n = 3024.









Convenience (n = 200; total brands = 49; brands per outlet = 2.1)
Pharmacies (4) 62 (88.6%) 1 (1.4%) 3 (4.3%) 0 2 (2.9%) 2 (2.9%) 70
PMVs (16) 97 (81.5%) 6 (5.0%) 9 (7.6%) 1 (0.8%) 2 (1.7%) 4 (3.4%) 119
Public health
facilities (2)
4 (80.0%) 1 (20.0%) 0 0 0 0 5
Market stalls (1) 6 (100.0%) 0 0 0 0 0 6
All outlets (23) 169 (84.5%)a, b 8 (4.0%) 12 (6.0%)c, d 1 (0.5%) 4 (2.0%) 6 (3.0%)e,
f
200
Mystery clients (n = 1919; total brands = 102; brands per outlet = 0.4)
Pharmacies (92) 803 (90.0%) 23 (2.6%) 25 (2.8%) 20 (2.2%) 16 (1.8%) 5 (0.6%) 892
PMVs (174) 94 (91.9%) 29 (3.0%) 7 (0.7%) 15 (1.5%) 9 (0.9%) 19 (2.0%) 973
Public health
facilities (13)
51 (94.4%) 3 (5.6%) Acceptable 0 0 0 0 54
All outlets (279) 1748 (91.1%)a 55 (2.9%) 32 (1.7%)c 35 (1.8%) 25 (1.3%) 24
(1.2%)e
1919
Overt (n = 905; total brands = 79; brands per outlet = 0.7)
Pharmacies (54) 488 (89.4%) 27 (4.9%) 16 (2.9%) 7 (1.3%) 8 (1.5%) 0 546
PMVs (65) 340 (94.7%) 7 (1.9%) 5 (1.4%) 1 (0.3%) 1 (0.3%) 5 (1.4%) 359
Public health
facilities (0)
- - - - - - -
All outlets (119) 828 (91.5%)b 34 (3.8%) 21 (2.3%)d 8 (0.9%) 9 (1.0%) 5 (0.6%) 905
ACAs = artemisinin containing antimalarial; AD = artemisinin derivative (always the ACAs); PD = partner drug (always the non-ACAs); PMVs = patent
medicine vendors. Substandard = genuine medicines produced by legitimate manufacturers that do not satisfy the pharma set quality specifications.
Degraded = result from exposure of good quality medicines to excessive heat and humidity. Falsified = deliberately and fraudulently mislabelled with
respect to identity and/or source. Include both branded and generic products and may include wrong ingredients or no active ingredients or counterfeited
packaging. Significant difference between sampling approaches for each quality category are indicated as follows: between convenience and mystery
clients =
a (p = 0.002),
c (p<0.001),
e (p = 0.046); between convenience and overt =
b, f (p = 0.002),
d (p = 0.006). Other comparisons were not significantly different (p>0.05).
doi:10.1371/journal.pone.0125577.t002
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injections (1) and tablets (149), were purchased for testing. The availability of monotherapy
tablets (artesunate and dihydroartemisinin) did not differ according to sampling approach
[107/1819 (5.9%) by mystery and 42/860 (4.9% by overt; p = 0.29). The proportion of medica-
tions not produced by WHO prequalified manufacturers was significantly higher in pharma-
cies than patent medicine vendors in both sampling approaches (p<0.001 for both).
Risk factors for substandard, degraded and falsified drugs
Generic dihydroartemisinin formulations were more likely to be substandard, degraded or fal-
sified than artemether or artesunate formulations (Table 5). Samples labelled with the AMFm
logo or fromWHO prequalified manufacturers were more likely to be of good quality than
those that were not. However, four Coartem samples, batch number F2261, allegedly manufac-
tured by Novartis and with the AMFm logo, were found to be falsified, containing chloroxa-
zone instead of the stated APIs. The risk of a drug being of poor quality—predominantly
substandard and degraded—also differed according to stated country of manufacture while the
risk of buying a falsified drug was five times greater if it had been manufactured locally (stated
on the packaging as Nigeria) after controlling for other factors; adjusted odds ratio 5.0 (95% CI
1.9–13.2). In addition, the risk of buying a falsified drug amongst drugs purchased from a pat-
ent medicine vendor than amongst drugs purchased from a pharmacy; adjusted odds ratio 3.9
(95% CI 1.5–10.1).
At the time of analysis approximately 10% of the samples had exceeded their expiry date, a
factor also associated with poor quality. Of these 275 out of date samples, 59 (21.5%) were de-
termined to be of poor quality (substandard, degraded and falsified). Almost a third of these
out of date samples were suspensions as they were the last dose form type to be analysed due to
their complexity. As a quarter of these expired suspensions contained>115% of AD and/or
PD they therefore do not provide a reliable idea with regards to the relationship between drug
quality and expiration unlike degraded samples. Hence, it is unlikely that the inclusion of ex-
pired samples would have substantially affected the estimate of the overall proportion of poor
quality drugs found in this study.
Discussion
Reports of the quality of antimalarial drugs are not available for the majority of malaria endem-
ic countries [24]. This assessment of the quality of ACTs and AMTs purchased from pharma-
cies, patent medicine vendors and public health facilities in Enugu metropolis, Nigeria, found
Table 3. Quality of Artemisinin-Containing Antimalarials (ACAs) at 98 outlets visited during both mys-
tery clients and overt sampling in Enugu, Nigeria.
Sampling method
Variable Mystery clients Overt p-value
Outlets 98 of 277 (35.4%) 98 of 119 (82.4%)
Samples 720 721
Brands 78 (72.9%) 72 (67.3%) 0.37
Acceptable quality 669 (92.9%) 665 (92.2%) 0.62
Substandard 35 (4.9%) 46 (6.4%) 0.21
Degraded 7 (1.0%) 5 (0.7%) 0.56
Falsified 9 (1.3%) 5 (0.7%) 0.28
Total number of brands purchased were 107
doi:10.1371/journal.pone.0125577.t003
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Table 4. Description of all samples purchased usingmystery clients and overt sampling approaches in Enugu, Nigeria; N = 2865.
Mystery clients Overt
Variable Total samples Pharmacies PMVs p-valuea PHFs Total samples Pharmacies PMVs p-valuea
Combination therapies
AM-LUM 1145 (62.9%) 509 (59.0%) 597 (66.0%) 0.04 39 (73.6%) 581 (67.6%) 344 (66.4%) 237 (69.3%) 0.44
AS-ADQ 239 (13.1%) 117 (13.6%) 108 (11.9%) 0.72 14 (26.4%) 78 (9.1%) 48 (9.3%) 30 (8.8%) 0.97
AS-MEF 47 (2.6%) 32 (3.7%) 15 (1.7%) 0.71 0 25 (2.9%) 19 (3.7%) 6 (1.8%) 0.81
AS-SULDOX-PYR 12 (0.7%) 8 (0.9%) 4 (0.4%) 0.97 0 4 (0.5%) 2 (0.4%) 2 (0.6%) 0.97
AS-SULFMEX-PYR 28 (1.5%) 24 (2.8%) 4 (0.4%) 0.93 0 21 (2.4%) 18 (3.5%) 3 (0.9%) 0.83
DHA-PIP 344 (18.9%) 171 (19.8%) 173 (19.1%) 0.85 0 151 (17.6%) 87 (16.8%) 64 (18.7%) 0.73
ART-PIP 1 (0.1%) 0 1 (0.1%) - 0 0 0 0
DHA-ADQ 3 (0.2%) 1 (0.1%) 2 (0.2%) - 0 0 0 0
Total 1819b 862 904 53 860b 518 342
All monotherapies (suspensions n = 36, injectables n = 1, and tablets n = 149)
AM 1 (0.8%) 0 0 0 1 (50.0%) 0 0 0
DHA 14 (11.0%) 10 (21.3%) 4 (5.1%) 0.1 0 1 (1.7%) 0 1 (4.3%) 1.00
AS 112 (88.2%) 37 (78.7%) 74 (94.9%) <0.001 1 (50.0%) 58 (98.3%) 36 (100.0%) 22 (95.7%) 0.07
Total 127b 47 78 2 59b 36 23
Monotherapy tablets (n = 149)
AM 0 0 0 0 0 0 0
DHA 13 (12.1%) 10 (23.3%) 3 (4.8%) <0.01 0 1 (2.4%) 0 1 (5.0%) 0.48
AS 94 (87.9%) 33 (76.7%) 60 (95.2%) <0.01 1 (100.0%) 41 (97.6%) 22 (100.0%) 19 (95.0%) 0.48
Total 107b 43 63 1 42b 22 20
Dose form
Tablets 1710 (87.9%) 792 (87.2%) 866 (88.1%) 0.57 52 (94.5%) 774 (84.2%) 446 (80.5%) 328 (89.9%) <0.001
Capsules 5 (0.3%) 4 (4.4%) 0 - 1 (1.8%) 3 (0.3%) 2 (0.4%) 1 (0.3%)
Suspensions 187 (9.6%) 87 (9.6%) 99 (10.1%) 0.92 1 (1.8%) 131 (14.3%) 97 (17.5%) 34 (9.3%) 0.24
Injectables 1 (0.1%) 0 0 - 1 (1.8%) 0 0 0
Granules/powders 40 (2.1%) 24 (2.6%) 16 (1.6%) 0.83 0 11 (1.2%) 9 (1.6%) 2 (0.5%) 0.91
Soft gels 3 (0.2%) 1 (0.1%) 2 (0.2%) - 0 0 0 0
Total 1946 908 983 55 919 554 365
WHO prequalification
Not WHO prequalified 1386 (71.2%) 727 (80.0%) 638 (64.9%) <0.001 21 (38.2%) 702 (76.4%) 450 (81.2%) 252 (69.0%) <0.001
Stated region of manufacture
Africa 381 (19.6%) 182 (20.0%) 182 (18.5%) 0.66 17 (30.9%) 168 (18.3%) 96 (17.3%) 72 (19.7%) 0.69
Asia 1324 (68.0%) 619 (68.2%) 671 (68.3%) 1 34 (61.8%) 644 (70.1%) 387 (69.9%) 257 (70.4%) 0.89
Europe 90 (4.6%) 65 (7.2%) 25 (2.5%) 0.39 0 60 (6.5%) 47 (8.5%) 13 (3.6%) 0.30
North America 149 (7.7%) 42 (4.6%) 104 (10.6%) 0.25 3 (5.5%) 44 (4.8%) 21 (3.8%) 23 (6.3%) 0.70
Unknown 2 (0.1%) 0 1 (0.1%) - 1 (1.8%) 3 (0.3%) 3 (0.5%) 0
Total 1946 908 983 55 919 554 365
AM = artemether; ADQ = -amodiaquine; ART = artemisinin; AS = artesunate; DHA = dihydroartemisinin; LUM = lumefantrine; MEF = mefloquine;
PIP = piperaquine; PYR = pyrimethamine; SULDOX = sulfadoxine; SULFMEX = sulfamethoxypyridazine; PHCs = public health facilities; PMVs = patent
medicine vendors; WHO = World Health Organisation.
aonly pharmacies and patent medicine vendors were compared as public health facilities were not visited during the overt sampling approach.
bno significant difference (p = 0.29) between the proportion of monotherapy tablets purchased using the mystery clients (5.5%) and overt (4.6%)
sampling approaches.
doi:10.1371/journal.pone.0125577.t004
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that 9.2% of the drugs purchased were of poor quality, with 1.2% falsified, 1.3% degraded, and
6.8% substandard in one or more of the APIs. The reliability of these findings are supported by
the use of standardised sampling procedures, based on accurate contemporaneous sampling
frames. The chemical analyses were corroborated in three independent laboratories. Although
these results raise concerns, they are reassuring in comparison with a previous meta-analysis
which concluded that 35% of 2296 antimalarial drugs, purchased mainly as a small sample size
in 21 countries in Sub-Saharan Africa using the convenience method, failed chemical content
analysis [24, 25].
When comparing the estimates obtained in our study using different sampling approaches
the prevalence of poor quality drugs was highest for ACAs purchased using the convenience
sampling approach. This yielded a significantly higher proportion of poor quality (substandard
Table 5. Univariate andmultivariate analyses of associations of substandard, degraded and falsified samples with key risk factors (significant as-









The following are significant risk factors for poor quality (substandard, degraded and falsified) ACAsb
Generic type AM 1701 80 (4.7%) 1 1
DHA 501 72 (14.4%) 3.4 (2.4,4.9) 2.4 (1.6,3.4)
AS 622 43 (6.9%) 1.5 (1.0,2.2) 1.4 (0.9,2.2)
WHO prequalified/ QAACT not prequalified 2047 190 (9.3%) 1 1
Prequalified 777 5 (0.6%) 0.06 (0.02,0.15) 0.08 (0.02,0.3)
AMFm non AMFm drugs 2072 191 (9.3%) 1 1
AMFm drugs 752 4 (0.5%) 0.05 (0.02,0.13) 0.24 (0.1,0.8)
Region of stated country of
manufacture
Asia 1940 159 (8.2%) 1 1
Africa 546 30 (5.5%) 0.7 (0.4,1.0) 2.1 (1.3,3.2)
Europe 141 1 (0.7%) 0.08 (0.01,0.6) 0.04 (0.06,0.4)
North America/
unknown
197 5 (2.6%) 0.3 (0.1,0.7) 12.5 (2.7,56.9)
Expired at time of analysis not expired 2537 132 (5.2%) 1 1
expireda 275 59 (21.5%) 5.0 (3.6,6.9) 6.4 (4.4,9.3)
The following are significant risk factors specifically for falsified ACAsc
Outlet type Pharmacies 1438 5 (0.4%) 1 1
PMVs 1332 24 (1.8%) 4.2 (2.0,12.0) 3.9 (1.5,10.1)
public health facilities 54 0 1 1
Generic type AM 1701 8 (0.5%) 1 1
DHA 501 18 (3.6%) 7.8 (3.4,18.3) 5.9 (1.9,18.1)
AS 622 3 (0.5%) 1.0 (0.3,4.1) 0.9 (0.2,3.5)
Region of stated country of
manufacture
Asia 1940 7 (0.4%) 1 1
Africa 546 17 (3.1%) 8.9 (3.5,22.4) 5.0 (1.9,13.2)
Europe 141 0 1 1
North America/
unknown
197 5 (2.5%) 7.2 (2.4,21.1) 27.9 (5.2,149.4)
ACAs = artemisinin-containing antimalarials; AM = artemether; AMFm = Affordable Medicines Facility—malaria; AS = artesunate;
CI = confidence interval; DHA = dihydroartemisinin; LR = likelihood-ratio; PMVs = patent medicine vendors; QAACT = quality-assured
artemisinin combination therapy; WHO = World Health Organisation.
aof these 59 expired samples 58% were suspensions that were substandard, while only 8% were tablets that were degraded.
badjusted for generic type, WHO prequalification, AMFm status, manufacture region, expired at time of analysis.
cadjusted for outlet type, provider health related qualification, generic type, AMFm status, manufacture region.
doi:10.1371/journal.pone.0125577.t005
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and falsified) drugs than the mystery clients and overt sampling approaches (p<0.05 in both
cases). Though the latter mystery clients and overt approaches captured a larger number of
brands, which may have been the consequence of the greater number of outlets surveyed and
numbers of samples purchased Rather than the sampling methodology per se. Our findings
draw attention to the importance of representative sampling approaches to monitor the quality
of drugs accurately in a given geographic region and suggest that the prevalence of poor quality
drugs in sub-Saharan Africa could be overestimated from previous reports, which were largely
based on convenience sampling [24, 25].
Although direct comparison between the mystery and overt approaches is hampered by the
time between the surveys and rapid pace of change in the drug markets during this two-month
interval, resulting in variation both in number of outlets surveyed and variability in brands and
number of samples purchased, the quality of the drugs tested did not vary from the 98 outlets
visited by both approaches. As the quality of drugs purchased did not vary significantly be-
tween the mystery clients and overt approach our findings indicate that either strategy could be
effectively used to determine drug quality in a geographical region. However, as each approach
has its advantages and disadvantages the survey objectives must be considered to ensure that
the most appropriate sampling strategy is chosen (Table 6). For example, the overt approach
has the advantage of collecting additional information through the use of outlet questionnaires,
enabling detailed data to collect on sources as well as risk factors for poor quality drugs, at min-
imal added cost. However, there is greater potential risk of sampling bias with the overt ap-
proach, if for example outlet staff are aware of which drugs may be of poor quality, and
therefore either refuse to be sampled or differentially withhold some samples. The mystery cli-
ents approach has a lower inherent risk of sampling bias as outlets are unaware of the survey,
and could thus be a more effective way to identify falsified products. In our study both the mys-
tery and overt approaches yielded similar results for each classification of drug quality (accept-
able; substandard; degraded and falsified) indicating that the selection bias often assumed to be






•Lack of defined sampling frame of standardised approach
•Uncertainty in whether sampling is representative and therefore reliability of the
estimates of drug quality obtained
•Generalisability of findings may be weak
•Results may be difficult to replicate
Mystery clients •Use of defined sampling frame
•Can yield representative sample from all types of
outlets and/or brands
•Low risk of sampling bias in samples collected,
as outlets are unaware of survey
•Reliability and generalisability of results should be
strong
•Results can be replicated
•Sample will only be as comprehensive and/or representative as the sampling
frame that was used
•Need to authenticate and update sampling frame increases time and cost of
survey
•Information on sources of poor quality drugs is limited to brand, batch and
country of manufacture as stated on packaging
Overt •Use of defined sampling frame
•Can yield representative sample from all types of
outlets and/or brands
•Results can be replicated
•Can collect additional information at minimal
additional cost to mystery approach
•Sample will only be as comprehensive and/or representative as the sampling
frame that was used
•Need to authenticate and update sampling frame increases time and cost of
survey
•Possible risk of sampling bias in samples collected, if some outlets refuse to be
sampled or are aware of which samples might be poor quality and differentially
withhold these
•Reliability and generalisability of results may be compromised if sampling
bias occurs
doi:10.1371/journal.pone.0125577.t006
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the limitation of overt sampling was not a major concern in this setting. This would further
suggest that vendors are not necessarily aware of which drugs may be of poor quality.
Analyses of falsified samples using both HPLC and MS techniques confirmed the absence of
the stated APIs and examination of the packaging also showed them to be counterfeited e.g.
most notably the packets on AMFm logoed Coartem had a longer expiry date than used by
Novartis; packets of dihydroartemisinin/piperaquine manufactured in Nigeria and branded
“Waipa ACT Tablets” had a missing hologram. This existence of counterfeit products is a
major concern, since sick patients would be left untreated, thus representing a serious public
health risk. Moreover, a number of compounds other than the stated APIs on the packaging
were tentatively identified in these samples that have the potential to produce adverse effects
and could be toxic. A further concern is the availability of monotherapy tablets on two counts,
firstly these are not recommended by WHO for the treatment of uncomplicated Pfmalaria;
secondly, four of the 135 monotherapy samples were found to be falsified. The absence of one
of the stated API in an ACT and the availability of monotherapies increases the risk of drug re-
sistance and adverse effects [26].
Our results show that falsified drugs in this setting were most likely to be dihydroartemisi-
nin/piperaquine tablets, and that the risk of purchasing a falsified drug was greater from a pat-
ent medicine vendor than other sources. The PMV category included drug purchased from
small shops and grocery shops as well as specialised drug outlets. Our study did not however
sample drugs sold by market stalls or other unlicensed traders, and given the findings above
there is a potential that the risk of poor quality drugs may be greatest in this highly unregulated
sector. Obtaining reliable estimates of drug quality amongst unlicensed providers is particularly
challenging, hampered by factors such as lack of sampling frame, rapid turnover of outlets, pro-
viders fearing regulation and/or reprisal, staff safety and anonymity; but nevertheless should be
a priority for research in countries where a major share of antimalarial treatments are sought
from unregulated providers. It is reassuring that samples labelled with the AMFm logo or from
WHO pre-qualified manufacturers were less likely to have quality concerns. However, recent
findings in Angola where packets of Coartem bearing the AMFm logo, allegedly manufactured
by Novartis, were found to be falsified together with the findings in this study reinforce the
need to remain vigilant [27, 28, 29].
In conclusion, although the situation in Enugu metropolis, Nigeria was not as alarming has
been reported elsewhere in Sub-Saharan Africa [24, 25, 26, 27, 28, 30]—falsified, degraded and
substandard drugs were circulating in the market and highlights the need for routine monitor-
ing of drug quality. Furthermore, whilst convenience sampling can be useful to help identify
the presence of poor quality drugs and “hot spots” where these are sold, this unstandardised
method may overestimate their prevalence. Our findings demonstrate that a representative
sampling approach, is essential, and that either a mystery client or overt sampling approach,
can be used to accurately quantify and track the scale of ineffective drugs which jeopardise
treatment of a life threatening disease.
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